Navigation Links
LCS Constructors, Inc. Completes First Major Phase of Abraxis BioScience Project
Date:4/29/2010

IRVINE, Calif., April 29 /PRNewswire/ -- Abraxis BioScience initially engaged LCS Constructors, Inc. to perform an evaluation of the former ICN/Valient Pharmaceutical building in Costa Mesa, California prior to their purchasing this 165,000 square foot building. The "due diligence report" revealed an array of issues that required repair or retro-fit prior to occupying the building, and once the building purchase was complete, Abraxis called upon LCS to serve as Design-Builder for a multi-phase renovation.

With Senior Project Manager David P. Carlos leading the way and Superintendent Jim Koons heading up daily production, LCS recently completed significant seismic upgrades as well as restoring and renovating existing laboratory space to Abraxis' specifications. LCS was charged with ensuring that the end result would be a new "state-of-the-art" laboratory which includes labs for chemistry, biology, formulation, and a Biological Safety Lab 3 (BSL3).

The biggest challenges throughout the project were, literally, the seismic upgrades. Working on the second floor, the size and weight alone of the dampeners was too much to just place them anywhere. With each dampener between 15' and 19' long and weighing between 700 lbs and 1000 lbs each, they were just too large to install without significant planning.

The team strategized to figure out the best location for the dampeners which was both close to the work but out of the way, keeping both production and safety in mind. Because the seismic dampeners were not standard equipment, the installation presented other unique challenges in terms of tolerances. Additionally, in order to accurately plan for the installation of the dampeners, seismic models were created. These seismic models were a key element for understanding the purpose and the workings for this project.

"This has been a fantastic client and job to work on," stated Koons. And, although the team faced several unique challenges that accompanied these seismic upgrades, they were resourceful and that, combined with patience, planning and strategy, led to the successful completion of the first major phase of this project.

The relocation of Abraxis' research and development group from Marina Del Rey to Costa Mesa will provide the company more space to grow their operations. LCS was proud to renovate the new facility which will provide the technology necessary to propel Abraxis closer to their goals of finding new treatments for cancer and other pathological disorders.


'/>"/>
SOURCE LCS Constructors, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
Breaking Medicine News(10 mins):